Comparative Pharmacology
Head-to-head clinical analysis: ALINIA versus DARAPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALINIA versus DARAPRIM.
ALINIA vs DARAPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitazoxanide is a thiazolide antiparasitic agent that inhibits the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction, which is essential for anaerobic energy metabolism in parasites.
Daraprim (pyrimethamine) is a folic acid antagonist that inhibits dihydrofolate reductase (DHFR) in susceptible protozoa, thereby interfering with folate synthesis and blocking DNA synthesis and cell replication. It is synergistic with sulfonamides, which inhibit dihydropteroate synthase in the folate pathway.
500 mg orally twice daily for 3 days, with food.
50 mg orally once daily for 2 days, then 25 mg orally once daily for 4 weeks; for toxoplasmosis, a loading dose of 200 mg orally once daily for 1 day, followed by 50-75 mg orally once daily for 4-6 weeks, with folinic acid 10-25 mg daily.
None Documented
None Documented
Terminal half-life of tizoxanide is approximately 1.5-2 hours in patients with normal renal function; clinical context: short half-life requires twice-daily dosing.
Terminal elimination half-life is approximately 111 hours (range 54-148 hours) in adults. The long half-life allows weekly dosing for toxoplasmosis treatment.
Fecal (75-85% as tizoxanide), renal (5-10% as tizoxanide and conjugates), biliary (minor).
Primarily hepatic metabolism; renal excretion accounts for approximately 30% of elimination as unchanged drug and metabolites. Fecal excretion is minimal (<5%).
Category C
Category C
Antiprotozoal Agent
Antiprotozoal Agent